All In Biotech

Drug Trial Radar · NCT05318573

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 1, 2022

Primary completion

May 2029

Study completion Nov 2029

Sponsor

Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer

Conditions

  • Advanced Urothelial Carcinoma
  • Advanced Non Small Cell Lung Cancer

Interventions

  • PembrolizumabDrug

    Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832

  • FF-10832Drug

    Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the incidence of Treament Emergent Adverse Events (TEAE)Time frame: 7 years
  2. Duration of Stable Disease in MonotherapyTime frame: 7 years
  3. Duration of Stable Disease in Combination TherapyTime frame: 7 years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer and Blood Speciality Clinic

    Long Beach, California

  • Sharp Memorial Hospital (Oncology Clinical Research)

    San Diego, California

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • University of Kansas Cancer Center - Westwood

    Westwood, Kansas

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • University of Louisville Brown Cancer Center

    Louisville, Kentucky

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

    Detroit, Michigan

  • Washington University School of Medicine, Center for Adv Medicine

    St Louis, Missouri

  • Nebraska Cancer Specialists - Legacy

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada - Southern Hills

    Las Vegas, Nevada

  • Atlantic Health System / Morristown Medical Center

    Morristown, New Jersey

  • NYU Langone Health

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • TriHealth Cancer Institute; Good Samaritan Hospital

    Cincinnati, Ohio

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon

  • Hospital of the Univ of Pennsylvania Perlman Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • University of Wisconsin Clinical Science Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.